SEC Form 4 · accession 0001127602-18-036615
HAEMONETICS CORP · HAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard J Meelia
Director
Period of report
Dec 14, 2018
Accepted (ET)
Dec 18, 2018 · 5:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000313143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 14, 2018 | M | 8,196 | $36.37 | A | 36,803 | D | |
| Common StockF2,F1 | Dec 14, 2018 | S | 8,196 | $102.86 | D | 28,607 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F3 | $36.37 | Dec 14, 2018 | M | 8,196 | D | Jul 27, 2013 | Jul 27, 2019 | Common Stock | 8,196 | 0 | D |
Explanation of responses
- F1This number includes unvested restricted stock units previously reported.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.56 to $103.26, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.